StockData
International Stem Cell CORP logo

International Stem Cell CORP (ISCO) stock

ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.28+0.00 (+0.89%)

Close on Oct 19, 2026Market cap $2.27MP/E –Yield –

International Stem Cell operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

International Stem Cell's operating income for the twelve months ending Jun 30, 2026 was -$444.00K. For fiscal 2025 it was -$267.00K. The highest annual figure on record is -$68.00K in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$267.00K–
FY2024Dec 31, 2024-$68.00K–
FY2023Dec 31, 2023-$663.00K–
FY2022Dec 31, 2022-$183.00K–
FY2021Dec 31, 2021-$1.92M–
FY2020Dec 31, 2020-$2.82M–
FY2019Dec 31, 2019-$5.73M–
FY2018Dec 31, 2018-$3.47M–
FY2017Dec 31, 2017-$4.94M–
FY2016Dec 31, 2016-$4.85M–
FY2015Dec 31, 2015-$4.56M–
FY2014Dec 31, 2014-$8.68M–
FY2013Dec 31, 2013-$7.55M–
FY2012Dec 31, 2012-$9.82M–
FY2011Dec 31, 2011-$11.36M–
FY2010Dec 31, 2010-$10.46M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$35.00K-121.0%
Q1 FY2026Mar 31, 2026-$190.00K–
Q4 FY2025Dec 31, 2025-$313.00K-713.7%
Q3 FY2025Sep 30, 2025$94.00K–
Q2 FY2025Jun 30, 2025$167.00K+12.1%
Q1 FY2025Mar 31, 2025-$215.00K–
Q4 FY2024Dec 31, 2024$51.00K–
Q3 FY2024Sep 30, 2024-$90.00K–
Q2 FY2024Jun 30, 2024$149.00K–
Q1 FY2024Mar 31, 2024-$178.00K-9000.0%
Q4 FY2023Dec 31, 2023-$424.00K-795.1%
Q3 FY2023Sep 30, 2023-$97.00K–
Q2 FY2023Jun 30, 2023-$144.00K-564.5%
Q1 FY2023Mar 31, 2023$2.00K-92.0%
Q4 FY2022Dec 31, 2022$61.00K–
Q3 FY2022Sep 30, 2022-$300.00K–
Q2 FY2022Jun 30, 2022$31.00K–
Q1 FY2022Mar 31, 2022$25.00K–
Q2 FY2021Jun 30, 2021-$406.00K–
Q1 FY2021Mar 31, 2021-$567.00K–
Q4 FY2020Dec 31, 2020-$733.00K–
Q3 FY2020Sep 30, 2020-$798.00K–
Q2 FY2020Jun 30, 2020-$832.00K–
Q1 FY2020Mar 31, 2020-$455.00K–
Q4 FY2019Dec 31, 2019-$2.48M–
Q3 FY2019Sep 30, 2019-$813.00K–
Q2 FY2019Jun 30, 2019-$941.00K–
Q1 FY2019Mar 31, 2019-$1.49M–
Q4 FY2018Dec 31, 2018-$1.26M–
Q3 FY2018Sep 30, 2018-$663.00K–
Q2 FY2018Jun 30, 2018-$367.00K–
Q1 FY2018Mar 31, 2018-$1.19M–
Q4 FY2017Dec 31, 2017-$1.92M–
Q3 FY2017Sep 30, 2017-$970.00K–
Q2 FY2017Jun 30, 2017-$1.00M–
Q1 FY2017Mar 31, 2017-$1.05M–
Q4 FY2016Dec 31, 2016-$1.17M–
Q3 FY2016Sep 30, 2016-$1.26M–
Q2 FY2016Jun 30, 2016-$1.25M–

More International Stem Cell figures

See a number that looks wrong?